pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 33 Non-oncology: 24
Oncology: 9
Under Consideration for Negotiation 22 Non-oncology: 18
Oncology: 4
Completed Negotiations 398 With Letter of Intent: 344
Without agreement: 54
Negotiations That Were Not Pursued 79

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Otezla Celgene Inc. Psoriasis, moderate to severe plaque
Taltz Eli Lilly Canada Inc. Ankylosing spondylitis
Nyvepria Pfizer Canada Inc. febrile neutropenia in non-myeloid malignancies
Otezla Celgene Inc. Psoriatic Arthritis

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Opsumit Actelion Pharmaceuticals Ltd. Pulmonary Arterial Hypertension

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks